CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PALISADE BIO, INC.

PALI
$284MMicro Cap

Next catalyst

Phase 2October 2027

PALI-2108

Ulcerative Colitis (UC)

Get an email about PALI's next catalysts

Track PALISADE BIO (PALI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 2 past

Phase 2Next

PALI-2108 Phase 2 Est. Readout (ASCENTRA-UC)

October 2027~PALI-2108204

Estimated primary completion for PALI-2108 trial (NCT07845487) in Ulcerative Colitis (UC). Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)πŸ‡ΊπŸ‡ΈNorth AmericaCARLSBAD
Drug Pipeline

Frequently asked questions

What is in PALISADE BIO, INC.'s drug pipeline?β†’

CatalystAlert tracks 2 drug candidates in PALISADE BIO, INC.'s (PALI) pipeline across Phase 2. Its lead program is PALI-2108 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is PALISADE BIO, INC.'s next FDA catalyst?β†’

PALISADE BIO, INC.'s (PALI) next tracked catalyst is a Phase 2 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track PALI biotech catalysts?β†’

Add PALI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PALISADE BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply